- Home
- GOF vs PTGX Comparison
GOF vs PTGX Comparison
Compare GOF & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOF | PTGX |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GOF | PTGX |
|---|---|---|
| Price | $12.22 | $85.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $90.56 |
| AVG Volume (30 Days) | 789.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $296.47 |
| P/E Ratio | ★ N/A | $119.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.96 | $33.70 |
| 52 Week High | $16.76 | $96.54 |
Technical Indicators
Market Signals| Indicator | GOF | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 47.49 |
| Support Level | $11.97 | $84.11 |
| Resistance Level | $12.21 | $96.54 |
| Average True Range (ATR) | 0.12 | 3.32 |
| MACD | 0.07 | -0.87 |
| Stochastic Oscillator | 78.74 | 18.55 |
Price Performance
Historical ComparisonAbout GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.